Interaction of the p53 DNA-binding domain with its N-terminal extension modulates the stability of the p53 tetramer

Journal of Molecular Biology

Volumn 409, Issue 3, 2011, Pages 358-368

  Natan, Eviatar ^a   Baloglu, Cetin ^a   Pagel, Kevin ^b   Freund, Stefan M V ^a   Morgner, Nina ^b   Robinson, Carol V ^b   Fersht, Alan R ^a   Joerger, Andreas C ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cation interaction; electrospray mass spectrometry; oligomerization; protein structure; tumor suppressor

Indexed keywords

PROTEIN P53; PROTEIN SUBUNIT; TETRAMER;

AMINO TERMINAL SEQUENCE; ARTICLE; CRYSTAL STRUCTURE; DNA BINDING; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; THERMOSTABILITY; X RAY CRYSTALLOGRAPHY;

EID: 79956071405     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2011.03.047     Document Type: Article

References (52)

1. Vogelstein B., Lane D., and Levine A.J. Surfing the p53 network Nature 408 2000 307 310
2. Vousden K.H., and Prives C. Blinded by the light: the growing complexity of p53 Cell 137 2009 413 431
3. Joerger A.C., and Fersht A.R. The tumor suppressor p53: from structures to drug discovery Cold Spring Harbor Perspect. Biol. 2 2010 a000919
4. Joerger A.C., and Fersht A.R. Structural biology of the tumor suppressor p53 Annu. Rev. Biochem. 77 2008 557 582
5. Romer L., Klein C., Dehner A., Kessler H., and Buchner J. p53-a natural cancer killer: structural insights and therapeutic concepts Angew. Chem., Int. Ed. Engl. 45 2006 6440 6460 (Pubitemid 44563595)
6. Lee W., Harvey T.S., Yin Y., Yau P., Litchfield D., and Arrowsmith C.H. Solution structure of the tetrameric minimum transforming domain of p53 Nat. Struct. Biol. 1 1994 877 890 (Pubitemid 24974811)
7. Jeffrey P.D., Gorina S., and Pavletich N.P. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms Science 267 1995 1498 1502
8. Clore G.M., Ernst J., Clubb R., Omichinski J.G., Kennedy W.M., and Sakaguchi K. Refined solution structure of the oligomerization domain of the tumour suppressor p53 Nat. Struct. Biol. 2 1995 321 333
9. Brandt T., Petrovich M., Joerger A.C., and Veprintsev D.B. Conservation of DNA-binding specificity and oligomerisation properties within the p53 family BMC Genomics 10 2009 628
10. Joerger A.C., Rajagopalan S., Natan E., Veprintsev D.B., Robinson C.V., and Fersht A.R. Structural evolution of p53, p63, and p73: implication for heterotetramer formation Proc. Natl Acad. Sci. USA 106 2009 17705 17710
11. Rajagopalan S., Huang F., and Fersht A.R. Single-molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53 Nucleic Acids Res. 39 2009 2294 2303
12. Natan E., Hirschberg D., Morgner N., Robinson C.V., and Fersht A.R. Ultraslow oligomerization equilibria of p53 and its implications Proc. Natl Acad. Sci. USA 106 2009 14327 14332
13. Tidow H., Melero R., Mylonas E., Freund S.M., Grossmann J.G., and Carazo J.M. Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex Proc. Natl Acad. Sci. USA 104 2007 12324 12329 (Pubitemid 47206136)
14. Melero R., Rajagopalan S., Lazaro M., Joerger A.C., Brandt T., and Veprintsev D.B. Electron microscopy studies on the quaternary structure of p53 reveal different binding modes for p53 tetramers in complex with DNA Proc. Natl Acad. Sci. USA 108 2011 557 562
15. Lill N.L., Grossman S.R., Ginsberg D., DeCaprio J., and Livingston D.M. Binding and modulation of p53 by p300/CBP coactivators Nature 387 1997 823 827 (Pubitemid 27270910)
16. Thut C.J., Chen J.L., Klemm R., and Tjian R. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60 Science 267 1995 100 104
17. Di Lello P., Jenkins L.M., Jones T.N., Nguyen B.D., Hara T., and Yamaguchi H. Structure of the Tfb1/p53 complex: insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53 Mol. Cell 22 2006 731 740
18. Teufel D.P., Bycroft M., and Fersht A.R. Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2 Oncogene 28 2009 2112 2118
19. Wells M., Tidow H., Rutherford T.J., Markwick P., Jensen M.R., and Mylonas E. Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain Proc. Natl Acad. Sci. USA 105 2008 5762 5767 (Pubitemid 351758446)
20. Weinberg R.L., Veprintsev D.B., and Fersht A.R. Cooperative binding of tetrameric p53 to DNA J. Mol. Biol. 341 2004 1145 1159 (Pubitemid 39092307)
21. Lubin D.J., Butler J.S., and Loh S.N. Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function J. Mol. Biol. 395 2010 705 716
22. Pavletich N.P., Chambers K.A., and Pabo C.O. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots Genes Dev. 7 1993 2556 2564 (Pubitemid 24021012)
23. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., and Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database Hum. Mutat. 28 2007 622 629 (Pubitemid 46744292)
24. Joerger A.C., and Fersht A.R. Structure-function-rescue: the diverse nature of common p53 cancer mutants Oncogene 26 2007 2226 2242 (Pubitemid 46536643)
25. Friedler A., Veprintsev D.B., Hansson L.O., and Fersht A.R. Kinetic instability of p53 core domain mutants: implications for rescue by small molecules J. Biol. Chem. 278 2003 24108 24112 (Pubitemid 36830245)
26. Bullock A.N., Henckel J., and Fersht A.R. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy Oncogene 19 2000 1245 1256 (Pubitemid 30160617)
27. Butler J.S., and Loh S.N. Kinetic partitioning during folding of the p53 DNA binding domain J. Mol. Biol. 350 2005 906 918 (Pubitemid 40943450)
28. Butler J.S., and Loh S.N. Folding and misfolding mechanisms of the p53 DNA binding domain at physiological temperature Protein Sci. 15 2006 2457 2465 (Pubitemid 44771683)
29. Boeckler F.M., Joerger A.C., Jaggi G., Rutherford T.J., Veprintsev D.B., and Fersht A.R. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug Proc. Natl Acad. Sci. USA 105 2008 10360 10365
30. Basse N., Kaar J.L., Settanni G., Joerger A.C., Rutherford T.J., and Fersht A.R. Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant Chem. Biol. 17 2010 46 56
31. Xu J., Reumers J., Couceiro J.R., De Smet F., Gallardo R., and Rudyak S. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors Nat. Chem. Biol. 7 2011 285 295
32. Joerger A.C., Allen M.D., and Fersht A.R. Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations J. Biol. Chem. 279 2004 1291 1296 (Pubitemid 38082653)
33. Davis I.W., Leaver-Fay A., Chen V.B., Block J.N., Kapral G.J., and Wang X. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids Nucleic Acids Res. 35 2007 W375 W383
34. Wang Y., Rosengarth A., and Luecke H. Structure of the human p53 core domain in the absence of DNA Acta Crystallogr., Sect. D: Biol. Crystallogr. 63 2007 276 281 (Pubitemid 46438519)
35. Gallivan J.P., and Dougherty D.A. Cation-pi interactions in structural biology Proc. Natl Acad. Sci. USA 96 1999 9459 9464
36. Ang H.C., Joerger A.C., Mayer S., and Fersht A.R. Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains J. Biol. Chem. 281 2006 21934 21941 (Pubitemid 44181897)
37. Nikolova P.V., Henckel J., Lane D.P., and Fersht A.R. Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability Proc. Natl Acad. Sci. USA 95 1998 14675 14680 (Pubitemid 29003689)
38. van Dieck J., Fernandez-Fernandez M.R., Veprintsev D.B., and Fersht A.R. Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers J. Biol. Chem. 284 2009 13804 13811
39. Rajagopalan S., Jaulent A.M., Wells M., Veprintsev D.B., and Fersht A.R. 14-3-3 activation of DNA binding of p53 by enhancing its association into tetramers Nucleic Acids Res. 36 2008 5983 5991
40. Schumacher B., Mondry J., Thiel P., Weyand M., and Ottmann C. Structure of the p53 C-terminus bound to 14-3-3: implications for stabilization of the p53 tetramer FEBS Lett. 584 2010 1443 1448
41. Cho Y., Gorina S., Jeffrey P.D., and Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations Science 265 1994 346 355 (Pubitemid 24259959)
42. Chen Y., Dey R., and Chen L. Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer Structure 18 2010 246 256
43. Kitayner M., Rozenberg H., Rohs R., Suad O., Rabinovich D., Honig B., and Shakked Z. Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs Nat. Struct. Mol. Biol. 17 2010 423 429
44. Weinberg R.L., Veprintsev D.B., Bycroft M., and Fersht A.R. Comparative binding of p53 to its promoter and DNA recognition elements J. Mol. Biol. 348 2005 589 596 (Pubitemid 40515671)
45. Joerger A.C., Ang H.C., Veprintsev D.B., Blair C.M., and Fersht A.R. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations J. Biol. Chem. 280 2005 16030 16037 (Pubitemid 40616727)
46. Joerger A.C., Ang H.C., and Fersht A.R. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs Proc. Natl Acad. Sci. USA 103 2006 15056 15061 (Pubitemid 44583163)
47. Leslie A.G. Integration of macromolecular diffraction data Acta Crystallogr., Sect. D: Biol. Crystallogr. 55 1999 1696 1702 (Pubitemid 29504424)
48. Evans P. Scaling and assessment of data quality Acta Crystallogr., Sect. D: Biol. Crystallogr. 62 2006 72 82
49. McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., and Read R.J. Phaser crystallographic software J. Appl. Crystallogr. 40 2007 658 674 (Pubitemid 47080256)
50. Adams P.D., Grosse-Kunstleve R.W., Hung L.W., Ioerger T.R., McCoy A.J., and Moriarty N.W. PHENIX: building new software for automated crystallographic structure determination Acta Crystallogr., Sect. D: Biol. Crystallogr. 58 2002 1948 1954 (Pubitemid 35337293)
51. Emsley P., Lohkamp B., Scott W.G., and Cowtan K. Features and development of Coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 66 2010 486 501
52. Hernandez H., and Robinson C.V. Determining the stoichiometry and interactions of macromolecular assemblies from mass spectrometry Nat. Protoc. 2 2007 715 726 (Pubitemid 47040033)